News
Exelixis (EXEL) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q2 2023 Earnings CallAug 01, 2023, 5:00 p.m. ET
Operator
Source Fool.com
Pfizer (PFE) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Pfizer (NYSE: PFE)Q2 2023 Earnings CallAug 01, 2023, 10:00 a.m. ET
Operator
Source Fool.com
Pfizer (PFE) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Pfizer (NYSE: PFE)Q2 2023 Earnings CallAug 01, 2023, 10:00 a.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q2 2023 Earnings CallAug 01, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q2 2023 Earnings CallAug 01, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q2 2023 Earnings CallAug 01, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Merck (MRK) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Merck (NYSE: MRK)Q2 2023 Earnings CallAug 01, 2023, 8:00 a.m. ET
Operator
Source Fool.com
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
3 Magnificent High-Yield Dividend Stocks to Buy Hand Over Fist in August
Any time is a good time for income investors to buy dividend stocks. But certain times are better than others for specific stocks.
I think that's the case for several great picks with a new month
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Biogen's (NASDAQ: BIIB) biggest problem in recent times has been growth. The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Biogen's (NASDAQ: BIIB) biggest problem in recent times has been growth. The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Biogen's (NASDAQ: BIIB) biggest problem in recent times has been growth. The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in
Why Novavax Stock Zoomed 13% Higher on Monday
News of a fresh COVID-19 surge sent numerous stockholders into the shares of vaccine maker Novavax (NASDAQ: NVAX) on the first trading day of the week. As a result, Novavax's shares popped more than
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) will soon likely be going head to head in the market for therapies that treat Alzheimer's disease. Both drug developers see the market for such
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) will soon likely be going head to head in the market for therapies that treat Alzheimer's disease. Both drug developers see the market for such
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) will soon likely be going head to head in the market for therapies that treat Alzheimer's disease. Both drug developers see the market for such
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Could This Stock Be the Next Biotech Buyout?
Shares of Reata Pharmaceuticals (NASDAQ: RETA) recently jumped about 54% higher in a single trading session. This biotech stock was already way up this year thanks to the recent approval of its
Could This Stock Be the Next Biotech Buyout?
Shares of Reata Pharmaceuticals (NASDAQ: RETA) recently jumped about 54% higher in a single trading session. This biotech stock was already way up this year thanks to the recent approval of its
Could This Stock Be the Next Biotech Buyout?
Shares of Reata Pharmaceuticals (NASDAQ: RETA) recently jumped about 54% higher in a single trading session. This biotech stock was already way up this year thanks to the recent approval of its
These 2 Stocks Are Heading for a Big Moment. Time to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) both are approaching a crucial moment in their stories. The biotech companies are awaiting regulatory decisions for
These 2 Stocks Are Heading for a Big Moment. Time to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) both are approaching a crucial moment in their stories. The biotech companies are awaiting regulatory decisions for
These 2 Stocks Are Heading for a Big Moment. Time to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) both are approaching a crucial moment in their stories. The biotech companies are awaiting regulatory decisions for
4 Top Stocks and 3 Top Cryptocurrencies for August
The stock market has rallied so far this year, particularly in the period between the last earnings season and this one. Companies now have to prove to Wall Street that their higher stock prices are
4 Top Stocks and 3 Top Cryptocurrencies for August
The stock market has rallied so far this year, particularly in the period between the last earnings season and this one. Companies now have to prove to Wall Street that their higher stock prices are